Join the Venetoclax group to help and get support from people like you.
Venetoclax News
Oldest Adults With Acute Myeloid Leukemia Benefit From Venetoclax
THURSDAY, May 16, 2024 – For older adults with acute myeloid leukemia (AML), venetoclax (VEN) combined with a hypomethylating agent (HMA) is safe and effective and can prolong survival, according to...
AbbVie Announces US FDA Approval of Venclexta (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients
NORTH CHICAGO, Ill., May 15, 2019 /PRNewswire/ – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Genentech Announces FDA Grants Venclexta Accelerated Approval for People With Newly-Diagnosed Acute Myeloid Leukemia or Those Who Are Ineligible For Intensive Induction Chemotherapy
South San Francisco, CA – November 21, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted...
Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
South San Francisco, CA – June 8, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta...
FDA Approves Venclexta (venetoclax) for Chronic Lymphocytic Leukemia with 17p Deletion
April 11, 2016 – The U.S. Food and Drug Administration today approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality...
Further information
Related condition support groups
Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia